John Levine, MD
Enriched profileProfessor of Medicine (Hematology and Medical Oncology) and Pediatrics; Director of BMT Clinical Research and Co-Director, Mount Sinai Acute GVHD International Consortium (MAGIC), The Tisch Cancer Institute · Icahn School of Medicine at Mount Sinai
John Levine is Professor of Medicine (Hematology and Medical Oncology) and Pediatrics; Director of BMT Clinical Research and Co-Director, Mount Sinai Acute GVHD International Consortium (MAGIC), The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai. OpenAlex indexes 396 publications with 20,140 citations (h-index 66); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
John Levine, MD, is Professor of Medicine (Hematology and Medical Oncology) and Pediatrics at Icahn School of Medicine at Mount Sinai. The public record shows 396 publications with 20,140 citations (h-index 66), centered on Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 17 companies, 3 NIH-funded awards (2014–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Hematopoietic Stem Cell Transplantation
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 36 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 174.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
Industry payments
Updated 16 Oct 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Mesoblast, Inc.Program year20252 payments$11,868openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20254 payments
- GlaxoSmithKline, LLC.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
55.1%SNRI30.6%Duloxetine Hcl100%Part D<11 patientsGabapentinoids24.5%Gabapentin100%Part D<11 patientsDermatology
22.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22.4%Acyclovir100%Part D<11 patientsCancer & immunology
22.4%Kinase inhibitor22.4%Jakafi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
3 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- Project 3: Risk Adapted Clinical Trials of GVHD Treatment
Icahn School of Medicine at Mount Sinai
FY2026$677,070P01CA039542 - BMT CTN Core - Mount Sinai Consortium
Icahn School of Medicine at Mount Sinai
FY2026$218,243UG1HL138645 - Validation of a novel and more accurate endpoint for GVHD clinical trials
Icahn School of Medicine at Mount Sinai
FY2026$126,750R21HL177578
Congress activity
Updated 16 Oct 2026
30 congress contributions (2004–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Evaluating thymic stromal lymphopoietin (TSLP) as a biomarker in acute graft versus host disease
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL.
Journal of clinical oncology
Article2026 - Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.
Blood immunology & cellular therapy
Article2026
Most-cited works
by citation count (OpenAlex)- 01Graft-versus-host diseaseArticle2,452 citations2009
- 02
- 03Recombinant human acid α-glucosidaseArticle777 citations2006
- 04Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemiaArticle574 citations2018
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Other
ncbi.nlm.nih.gov/myncbi/collections/mybibliography
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ncbi.nlm.nih.gov ↗ - LinkedIn
linkedin.com/in/john-levine-50741060
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/John-Levine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
healthtree.org/aml/community/directory/ny/mount-sinai-health-system-new-york-ny/john-levine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bmtctn.net ↗
- Board Certified
Pediatric Hematology-Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bmtctn.net ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →childrensoncologygroup.org ↗
- Panel member/author
ASTCT Committee on Practice Guidelines -- Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →astctjournal.org ↗ - Co-Director
Mount Sinai Acute GVHD International Consortium (MAGIC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →physicians.mountsinai.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center